Recent contributions of structure-based drug design to the development of antibacterial compounds
Tài liệu tham khảo
Begley, 2011, Fragment screening of infectious disease targets in a structural genomics environment, Methods Enzymol, 493, 533, 10.1016/B978-0-12-381274-2.00021-2
Grinter, 2014, Challenges applications: and recent advances of protein-ligand docking in structure-based drug design, Molecules, 19, 10150, 10.3390/molecules190710150
Kuenemann, 2015, In silico design of low molecular weight protein–protein interaction inhibitors: overall concept and recent advances, Prog Biophys Mol Biol, 119, 20, 10.1016/j.pbiomolbio.2015.02.006
Kellici, 2015, Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors, Molecules, 20, 3868, 10.3390/molecules20033868
2014
Mensa, 2014, Comparative mechanistic studies of brilacidin: daptomycin, and the antimicrobial peptide LL16, Antimicrob Agents Chemother, 58, 5136, 10.1128/AAC.02955-14
Schneider, 2014, Cyclic lipopeptides as antibacterial agents—potent antibiotic activity mediated by intriguing mode of actions, Int J Med Microbiol, 304, 37, 10.1016/j.ijmm.2013.08.009
Weiss, 2014, In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection, Antimicrob Agents Chemother, 58, 5714, 10.1128/AAC.02903-14
Seddon, 2012, Drug design for ever: from hype to hope, J Comput Aided Mol Des, 26, 137, 10.1007/s10822-011-9519-9
Berman, 2000, The protein data bank, Nucleic Acids Res, 28, 235, 10.1093/nar/28.1.235
Stacy, 2011, Structural genomics of infectious disease drug targets: the SSGCID, Acta Crystallogr Sect F: Struct Biol Cryst Commun, 67, 979, 10.1107/S1744309111029204
Harris, 2015, Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?, Lancet Infect Dis, 15, 475, 10.1016/S1473-3099(14)70950-8
Lahiri, 2013, Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases, Antimicrob Agents Chemother, 57, 2496, 10.1128/AAC.02247-12
Lahiri, 2014, Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance, Antimicrob Agents Chemother, 58, 5704, 10.1128/AAC.03057-14
Lahiri, 2015, Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48, ACS Chem Biol, 10, 591, 10.1021/cb500703p
Karpiuk, 2013, Looking for the new preparations for antibacterial therapy. II. Clinical trials; new beta-lactam antibiotics and beta-lactamase inhibitors, Przegl Epidemiol, 67
Ehmann, 2012, Avibactam is a covalent: reversible, non-beta-lactam beta-lactamase inhibitor, Proc Natl Acad Sci U S A, 109, 11663, 10.1073/pnas.1205073109
Basarab, 2013, Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents, J Med Chem, 56, 8712, 10.1021/jm401208b
Eakin, 2012, Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents, Antimicrob Agents Chemother, 56, 1240, 10.1128/AAC.05485-11
Brvar, 2012, Structure-based discovery of substituted 4,5-bithiazoles as novel DNA gyrase inhibitors, J Med Chem, 55, 6413, 10.1021/jm300395d
Wüthrich, 1986
Barrett, 2013, The quiet renaissance of protein nuclear magnetic resonance, Biochemistry, 52, 1303, 10.1021/bi4000436
Pellecchia, 2002, NMR in drug discovery, Nat Rev Drug Discov, 1, 211, 10.1038/nrd748
Pellecchia, 2008, Perspectives on NMR in drug discovery: a technique comes of age, Nat Rev Drug Discov, 7, 738, 10.1038/nrd2606
Klages, 2007, NMR-based screening: a powerful tool in fragment-based drug discovery, Analyst, 132, 692, 10.1039/B709658P
Dalvit, 2001, Unconditional pointer states from conditional master equations, Phys Rev Lett, 86, 373, 10.1103/PhysRevLett.86.373
Jahnke, 2001, Spin label enhanced NMR screening, J Am Chem Soc, 123, 3149, 10.1021/ja005836g
Vanwetswinkel, 2005, TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery, Chem Biol, 12, 207, 10.1016/j.chembiol.2004.12.004
Fejzo, 1999, The SHAPES strategy: an NMR-based approach for lead generation in drug discovery, Chem Biol, 6, 755, 10.1016/S1074-5521(00)80022-8
Hajduk, 1997, One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules, J Am Chem Soc, 119, 12257, 10.1021/ja9715962
Mayer, 1999, Characterization of ligand binding by saturation transfer difference NMR spectroscopy, Angew Chem Int Ed, 38, 1784, 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q
Wagstaff, 2013, Recent developments and applications of saturation transfer difference nuclear magnetic resonance (STD NMR) spectroscopy, Mol Biosyst, 9, 571, 10.1039/C2MB25395J
Begley, 2014, A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins, Antimicrob Agents Chemother, 58, 1458, 10.1128/AAC.01875-13
Yee, 2002, An NMR approach to structural proteomics, Proc Natl Acad Sci U S A, 99, 1825, 10.1073/pnas.042684599
Myler, 2009, The Seattle Structural Genomics Center for Infectious Disease (SSGCID), Infect Disord Drug Targets, 9, 493, 10.2174/187152609789105687
Habchi, 2014, Introducing protein intrinsic disorder, Chem Rev, 114, 6561, 10.1021/cr400514h
Shuker, 1996, Discovering high-affinity ligands for proteins: SAR by NMR, Science, 274, 1531, 10.1126/science.274.5292.1531
Zuiderweg, 2002, Mapping protein–protein interactions in solution by NMR spectroscopy, Biochemistry, 41, 1, 10.1021/bi011870b
Altmann, 2001, Microtubule-stabilizing agents: a growing class of important anticancer drugs, Curr Opin Chem Biol, 5, 424, 10.1016/S1367-5931(00)00225-8
Ojima, 2014, Drug discovery targeting cell division proteins: microtubules and FtsZ, Bioorg Med Chem, 22, 5060, 10.1016/j.bmc.2014.02.036
Lutkenhaus, 1997, Bacterial cell division and the Z ring, Annu Rev Biochem, 66, 93, 10.1146/annurev.biochem.66.1.93
Errington, 2003, Cytokinesis in bacteria, Microbiol Mol Biol Rev, 67, 52, 10.1128/MMBR.67.1.52-65.2003
Respicio, 2008, Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery, Tuberculosis (Edinb), 88, 420, 10.1016/j.tube.2008.03.001
Moy, 2000, Solution structure of ZipA: a crucial component of Escherichia coli cell division, Biochemistry, 39, 9146, 10.1021/bi0009690
Liu, 1999, Recruitment of ZipA to the division site by interaction with FtsZ, Mol Microbiol, 31, 1853, 10.1046/j.1365-2958.1999.01322.x
Tsao, 2006, Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design, Bioorg Med Chem, 14, 7953, 10.1016/j.bmc.2006.07.050
Domadia, 2007, Inhibition of bacterial cell division protein FtsZ by cinnamaldehyde, Biochem Pharmacol, 74, 831, 10.1016/j.bcp.2007.06.029
Plaza, 2010, Chrysophaentins A-H: antibacterial bisdiarylbutene macrocycles that inhibit the bacterial cell division protein FtsZ, J Am Chem Soc, 132, 9069, 10.1021/ja102100h
Marcelo, 2013, Interactions of bacterial cell division protein FtsZ with C8-substituted guanine nucleotide inhibitors. A combined NMR: biochemical and molecular modeling perspective, J Am Chem Soc, 135, 16418, 10.1021/ja405515r
Baugh, 2015, Increasing the structural coverage of tuberculosis drug targets, Tuberculosis (Edinb), 95, 142, 10.1016/j.tube.2014.12.003
Kling, 2015, Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins, Science, 348, 1106, 10.1126/science.aaa4690
Shirude, 2013, Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis, ACS Chem Biol, 8, 519, 10.1021/cb300510w
Stacy, 2015, Structural genomics support for infectious disease drug design, ACS Infect Dis, 1, 127, 10.1021/id500048p
Baugh, 2013, Combining functional and structural genomics to sample the essential Burkholderia structome, PLoS One, 8, e53851, 10.1371/journal.pone.0053851